Skip to main content
About Us
Image Credits
Contributor Info
RSS
Log In
Join
Twitter
E-Alerts
Visit StemJournal
Main menu
About
Image Credits
Contributor Info
E-Alerts
Chapters
Cellular and nuclear reprogramming
Ectoderm specification and differentiation
Endoderm specification and differentiation
Epigenetics
Genomics and proteomics
Germ cell and somatic stem cell biology in reproduction
Manufacturing
Mesoderm specification and differentiation
Niche biology, homing, and migration
Renewal
Stem cell immunology
Therapeutic prospects
Tissue engineering
Protocols
Ectoderm differentiation
Endoderm differentiation
Genome editing
Mesoderm differentiation
Pluripotent stem cells
PSC characterization
PSC genetic stability
Reprogramming
StemLabs
Stem Cell COREdinates
Core Facility Profiles
Boston Children's Hospital Human Neuron Core
Boston University Center for Regenerative Medicine iPSC Core
Columbia Stem Cell Initiative Stem Cell Core Facility
Harvard Stem Cell Institute iPS Core Facility
Stem Cell Protocols
Stem Cell Reagents
Other Resources
News & Profiles
Latest News
Stem Cell Institute Profiles
Journal Stream
Forum
Search form
Search
You are here
Home
Biblio
Author
Title
[
Type
]
Year
Filters:
Author
is
Zhang, Haixiao
[Clear All Filters]
Journal Article
Zheng X
,
Gao H
,
Lu N
,
Wang M
,
Zhang H
,
Zheng Y
,
Shen B
,
Cao Y
,
Chen X
,
Zhai W
, et al.
Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms.
Ann Hematol. 2023.
PubMed
Google Scholar
Wang J
,
Wang Q
,
Zhang H
,
He Y
,
Huang Y
,
Zhang R
,
Wei J
,
Ma Q
,
Pang A
,
Yang D
, et al.
Moderate to severe marrow fibrosis as a more advanced risk factor for MDS and MDS-AML patients with excess of blasts receiving allogeneic hematopoietic stem cell transplantation.
Transplant Cell Ther. 2021.
PubMed
Google Scholar
Zhang H
,
Zheng X
,
Guo W
,
Xia Y
,
Zhang R
,
Zhai W
,
Chen X
,
Ma Q
,
Yang D
,
Wei J
, et al.
Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system.
Exp Hematol Oncol. 2024;13(1):16.
PubMed
Google Scholar
Cao Y
,
Zheng X
,
Zhang H
,
Wang M
,
Guo W
,
Chen X
,
Zhai W
,
Wei J
,
Yang D
,
Huang Y
, et al.
Refractory patients with favorable/intermediate-risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation.
Hematol Oncol. 2023.
PubMed
Google Scholar